ALUMIS INC
NASDAQ: ALMS (Alumis Inc.)
Last update: 7 hours ago26.50
-0.14 (-0.53%)
| Previous Close | 26.64 |
| Open | 26.46 |
| Volume | 1,762,190 |
| Avg. Volume (3M) | 1,270,387 |
| Market Cap | 3,378,537,472 |
| Price / Sales | 325.70 |
| Price / Book | 5.99 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2026 |
| Operating Margin (TTM) | -583.86% |
| Diluted EPS (TTM) | -11.24 |
| Total Debt/Equity (MRQ) | 18.94% |
| Current Ratio (MRQ) | 3.73 |
| Operating Cash Flow (TTM) | -291.17 M |
| Levered Free Cash Flow (TTM) | -169.99 M |
| Return on Assets (TTM) | -101.07% |
| Return on Equity (TTM) | -247.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Bullish |
| Biotechnology (Global) | Bullish | Bullish | |
| Stock | Alumis Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 53.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 31 Dec 2025 | 15,139,706 |
| Samsara Biocapital, Llc | 31 Mar 2026 | 6,345,219 |
| Foresite Capital Management V, Llc | 31 Mar 2026 | 5,896,995 |
| Venbio Partners Llc | 31 Mar 2026 | 4,528,408 |
| Foresite Capital Management Vi Llc | 31 Mar 2026 | 4,247,670 |
| Cormorant Asset Management, Lp | 31 Mar 2026 | 3,949,241 |
| Nextech Invest, Ltd. | 31 Mar 2026 | 3,540,998 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | 28.14 | - | 3,553 | 99,981 |
| MACHADO PATRICK | 28.14 | - | 3,553 | 99,981 |
| SRIVASTAVA SAPNA | 28.14 | - | 3,553 | 99,981 |
| TETRAULT LYNN A. | 28.14 | - | 3,553 | 99,981 |
| YAO ZHENGBIN | 28.14 | - | 3,553 | 99,981 |
| Aggregate Net Quantity | 17,765 | |||
| Aggregate Net Value ($) | 499,907 | |||
| Aggregate Avg. Buy ($) | 28.14 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | 30 Jun 2026 | Acquired (+) | 3,553 | 28.14 | 99,981 |
| MACHADO PATRICK | Director | 30 Jun 2026 | Acquired (+) | 3,553 | 28.14 | 99,981 |
| SRIVASTAVA SAPNA | Director | 30 Jun 2026 | Acquired (+) | 3,553 | 28.14 | 99,981 |
| YAO ZHENGBIN | Director | 30 Jun 2026 | Acquired (+) | 3,553 | 28.14 | 99,981 |
| TETRAULT LYNN A. | Director | 30 Jun 2026 | Acquired (+) | 3,553 | 28.14 | 99,981 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |